当前位置: X-MOL 学术J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Corrections to Discovery of (Z)-5-(4-Methoxybenzylidene)thiazolidine-2,4-dione, a Readily Available and Orally Active Glitazone for the Treatment of Concanavalin A-Induced Acute Liver Injury of BALB/c Mice
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2010-04-19 00:00:00 , DOI: 10.1021/jm100431z
Youfu Luo , Liang Ma , Hao Zheng , Lijuan Chen , Rui Li , Chunmei He , Shengyong Yang , Xia Ye , Zhizhi Chen , Zicheng Li , Yan Gao , Jing Han , Gu He , Li Yang , Yuquan Wei

Page 274. In line 9 of first paragraph in the left column, refs 17 and 18 should be present at the end of the sentence. The correct presentation of the sentence is as follows: Fifty-three compounds were synthesized through solution parallel synthesis strategy, with four of them (2g, 2h, 4f, and 6h) exhibiting high inhibitory effects on the chemotaxis of RAW264.7 with IC50 values ranging from 0.72 to 20.47 μM.17,18 Page 281. In the right column, two new references should be present as refs 17 and 18 and the original refs 17, 18, 19 should be relabeled to refs 19, 20, and 21, respectively. The correct presentation is as follows: (17) Bruno, G., Costantino, L., Curing, C., Maccari, R., Monforte, F., Nicolo, F., Ottana, R., and Vigorita, M. G.Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem. 2002, 10, 1077−1084. (18) Maccari, R., Ottana, R., Curing, C., Vigorita, M. G., Rakowitz, D., Steind, T., and Langer, T.Structure−activity relationships and molecular modeling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors. Bioorg. Med. Chem. 2005, 13, 2809−2823. (19) Xu, Z., Knaak, C., Ma, J., Beharry, Z. M., McInnes, C., Wang, W., Kraft, A. S., and Smith, C. D.Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J. Med. Chem. 2009, 52, 74−86. (20) Camps, M., Ruckle, T., Ji, H., Ardissone, V., Rintelen, F., Shaw, J., Ferrandi, C., Chabert, C., Gillieron, C., Francon, B., Martin, T., Gretener, D., Perrin, D., Leroy, D., Vitte, P.-A., Hirsch, E., Wymann, M. P., Cirillo, R., Schwarz, M. K., and Rommel, C.Blockade of PI3kg suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 2005, 11, 936−941. (21) Wang, Z., Wu, X., Song, L., Wang, Y., Hu, X., Luo, Y., Chen, Z., Ke, J., Peng, X., He, C., Zhang, W., Chen, L., and Wei, Y.Phosphoinositide 3-kinase γ inhibitor ameliorates concanavalin A-induced hepatic injury in mice. Biochem. Biophys. Res. Commun. 2009, 386, 569−574. This article has not yet been cited by other publications.

中文翻译:

更正发现(Z)-5-(4-甲氧基苄叉基)噻唑烷-2,4-二酮(一种现成的口服口服格列酮治疗伴刀豆球蛋白A引起的BALB / c小鼠急性肝损伤的治疗方法)

Page 274.左栏中第一段的第9行中,引用17和18应该出现在句子的末尾。该句子的正确表示如下:通过溶液平行合成策略合成了53种化合物,其中四种(2g2h4f6h)对具有IC 50的RAW264.7的趋化性具有高抑制作用值范围为0.72至20.47μM。17,18 Page 281.在右栏中,应该出现两个新的引用,分别是引用17和18,原始引用17、18、19应该分别重新标记为引用19、20和21。正确的演示如下:(17)布鲁诺(G.),哥伦比亚(Costantino),库林(C.),马卡里(R.),蒙福特(F.),尼古拉(N.),奥塔纳(R.)和维戈里塔(MG)5-亚芳基-2,4-噻唑烷二酮的合成及醛糖还原酶抑制活性。Bioorg。中 化学 2002年10,1077-1084。(18)Maccari,R.,Ottana,R.,Curing,C.,Vigorita,MG,Rakowitz,D.,Steind,T.,and Langer,T.具有醛糖还原酶抑制剂活性的5-亚芳基-2,4-噻唑烷二酮的结构活性关系和分子模型。Bioorg。中 化学 2005年13,2809至2823年。(19)Xu,Z.,Knaak,C.,Ma,J.,Beharry,ZM,McInnes,C.,Wang,W.,Kraft,A​​S和Smith,CDPim-1和Pim-2蛋白激酶新型抑制剂的合成和评价。J. Med。化学 200952,74-86。(20)坎普斯(Camps M.),鲁克(Ruckle),T。,吉(J.H.),阿迪松(V. Ardissone),V。,林特伦(Rintelen),F。,肖(Shaw),J。马丁·T·马丁,格雷特纳·D,珀林·D。,勒罗伊·D,维特,P.-A。,赫斯,E。,怀曼,国会议员,西里洛,R。,施瓦茨,MK和罗梅尔。在类风湿关节炎小鼠模型中,PI3kg的阻滞抑制关节发炎和损伤。纳特 中 2005年11,936-941。(21)王Z.,吴X.,宋L.,王Y.,胡X.,罗Y.,陈Z.,柯J.,彭X.,何C., Zhang W,Chen L.,and Wei Y.磷酸肌醇3-激酶γ抑制剂改善了伴刀豆球蛋白A引起的小鼠肝损伤。生化。生物物理学。Res。社区 2009年386,569-574。本文尚未被其他出版物引用。
更新日期:2010-04-19
down
wechat
bug